Literature DB >> 26772899

Differential Effects of Dexamethasone and Doxycycline on Inflammation and MMP Production in Murine Alkali-Burned Corneas Associated with Dry Eye.

Fang Bian1, Flavia S A Pelegrino1, Johanna Tukler Henriksson1, Stephen C Pflugfelder1, Eugene A Volpe1, De-Quan Li1, Cintia S de Paiva2.   

Abstract

Alkali burns to the cornea are among the most devastating injuries to the eye. The purpose of this study was to evaluate the effects of dexamethasone (Dex) or doxycycline (Doxy) on protease activity and corneal complications in a combined model (CM) of alkali burn and dry eye. C57BL/6 mice were subjected to the CM for 2 or 5 days (D). Mice were topically treated either with Dex (0.1%), Dox (0.025%) or vehicle QID and observed daily for appearance of corneal perforation. Quantitative real time PCR was performed to measure expression of inflammation cytokines and matrix metalloproteinases (MMPs) in whole cornea lysates. No perforations were observed in the Dex-treated corneas. All wounds in Doxy-treated corneas were closed 2D post-injury, and they had significantly lower corneal opacity scores at days 4 and 5 post-injury compared to BSS treatment. Dex-treated corneas had the lowest corneal opacity scores. Dex treatment significantly decreased expression of IL-1β, IL-6, MMPs -1, -9, -13, and TIMP-1 after 2 days but increased levels of MMP-8, while Doxy treatment significantly decreased IL-1β, IL-6, MMP-8, and -9, compared to vehicle. Decreased MMP-1, -9 and -13 immunoreactivity and gelatinolytic activity were seen in corneas treated with Doxy and Dex compared to vehicle. Increased neutrophil infiltration and myeloperoxidase activity was noted in the vehicle group compared to Dex 2 days post-injury. These findings demonstrate that early initiation of anti-inflammatory therapy is very efficacious in preserving corneal clarity and facilitating wound healing, while modulating MMP production and suppressing neutrophil infiltration.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MMPs; alkali injury; corticoid; dexamethasone; doxycycline; dry eye; neutrophils; ocular perforation

Mesh:

Substances:

Year:  2016        PMID: 26772899      PMCID: PMC4842328          DOI: 10.1016/j.jtos.2015.11.006

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  60 in total

1.  Regulation of MMP-9 production by human corneal epithelial cells.

Authors:  D Q Li; B L Lokeshwar; A Solomon; D Monroy; Z Ji; S C Pflugfelder
Journal:  Exp Eye Res       Date:  2001-10       Impact factor: 3.467

Review 2.  Chemical and thermal injuries of the eyes. Surgical and medical treatment based on clinical and pathophysiological findings.

Authors:  M Reim; C Redbrake; N Schrage
Journal:  Arch Soc Esp Oftalmol       Date:  2001-02

3.  Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.

Authors:  Efdal Yoeruek; Focke Ziemssen; Sigrid Henke-Fahle; Olcay Tatar; Aysegül Tura; Salvatore Grisanti; Karl U Bartz-Schmidt; Peter Szurman
Journal:  Acta Ophthalmol       Date:  2007-11-08       Impact factor: 3.761

4.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase.

Authors:  L Kjeldsen; A H Johnsen; H Sengeløv; N Borregaard
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

5.  The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism.

Authors:  S Gilbertson-Beadling; E A Powers; M Stamp-Cole; P S Scott; T L Wallace; J Copeland; G Petzold; M Mitchell; S Ledbetter; R Poorman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  An inhibitor of the matrix metalloproteinase synthesized by rabbit corneal epithelium.

Authors:  M E Fini; T Y Cui; A Mouldovan; D Grobelny; R E Galardy; S J Fisher
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-10       Impact factor: 4.799

7.  Characteristics of polymorphonuclear leukocyte infiltration into the alkali burned eye and the influence of sodium citrate.

Authors:  C A Paterson; R N Williams; A V Parker
Journal:  Exp Eye Res       Date:  1984-12       Impact factor: 3.467

8.  Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9.

Authors:  Kalpana Gupta; Meenakshi Shukla; Jack B Cowland; Charles J Malemud; Tariq M Haqqi
Journal:  Arthritis Rheum       Date:  2007-10

9.  Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer.

Authors:  Frank J G M Kubben; Cornelis F M Sier; Lukas J A C Hawinkels; Harald Tschesche; Wim van Duijn; Kim Zuidwijk; Johan J van der Reijden; Roeland Hanemaaijer; Gerrit Griffioen; Cornelis B H W Lamers; Hein W Verspaget
Journal:  Eur J Cancer       Date:  2007-07-02       Impact factor: 9.162

10.  Immunosuppression and selective inflammatory cell depletion. Studies on a guinea pig model of corneal ulceration after ocular alkali burning.

Authors:  C S Foster; R P Zelt; T Mai-Phan; K R Kenyon
Journal:  Arch Ophthalmol       Date:  1982-11
View more
  23 in total

1.  MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions.

Authors:  Fang Bian; Changjun Wang; Johanna Tukler-Henriksson; Stephen C Pflugfelder; Caterina Camodeca; Elisa Nuti; Armando Rossello; De-Quan Li; Cintia S de Paiva
Journal:  J Cell Physiol       Date:  2016-03-28       Impact factor: 6.384

2.  Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells.

Authors:  Vibhuti Agrahari; Guorong Li; Vivek Agrahari; Iris Navarro; Kristin Perkumas; Abhirup Mandal; W Daniel Stamer; Ashim K Mitra
Journal:  Nanomedicine (Lond)       Date:  2017-07-31       Impact factor: 5.307

3.  Matrix Metalloproteinase-Deactivating Contact Lens for Corneal Melting.

Authors:  Chelsi Lopez; Shiwha Park; Seth Edwards; Selina Vong; Shujie Hou; Minyoung Lee; Hunter Sauerland; Jung-Jae Lee; Kyung Jae Jeong
Journal:  ACS Biomater Sci Eng       Date:  2019-01-04

Review 4.  Corneal toxicity induced by vesicating agents and effective treatment options.

Authors:  Dinesh G Goswami; Neera Tewari-Singh; Rajesh Agarwal
Journal:  Ann N Y Acad Sci       Date:  2016-06-21       Impact factor: 5.691

Review 5.  Glucocorticoid receptor signaling in the eye.

Authors:  Rania S Sulaiman; Mahita Kadmiel; John A Cidlowski
Journal:  Steroids       Date:  2017-11-10       Impact factor: 2.668

Review 6.  Chemical eye injury: pathophysiology, assessment and management.

Authors:  Harminder S Dua; Darren Shu Jeng Ting; Ahmed Al Saadi; Dalia G Said
Journal:  Eye (Lond)       Date:  2020-06-22       Impact factor: 3.775

7.  Doxycycline Reduces Scar Thickness and Improves Collagen Architecture.

Authors:  Alessandra L Moore; Heather E desJardins-Park; Bryan A Duoto; Shamik Mascharak; Matthew P Murphy; Dre M Irizarry; Deshka S Foster; Ruth E Jones; Leandra A Barnes; Clement D Marshall; Ryan C Ransom; Gerlinde Wernig; Michael T Longaker
Journal:  Ann Surg       Date:  2020-07       Impact factor: 13.787

Review 8.  The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review).

Authors:  Hongyan Zhou; Wensong Zhang; Miaomiao Bi; Jie Wu
Journal:  Int J Mol Med       Date:  2016-08-04       Impact factor: 4.101

9.  Dexamethasone Drug Eluting Nanowafers Control Inflammation in Alkali-Burned Corneas Associated With Dry Eye.

Authors:  Fang Bian; Crystal S Shin; Changjun Wang; Stephen C Pflugfelder; Ghanashyam Acharya; Cintia S De Paiva
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-06-01       Impact factor: 4.799

10.  Protective outcomes of low-dose doxycycline on renal function of Wistar rats subjected to acute ischemia/reperfusion injury.

Authors:  Aline L Cortes; Sabrina R Gonsalez; Lilimar S Rioja; Simone S C Oliveira; André L S Santos; Minolfa C Prieto; Paulo A Melo; Lucienne S Lara
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-10-05       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.